Predicting Response to Intravesical Therapy in Non–muscle-invasive Bladder Cancer

Novel nomograms that combine clinicopathological criteria with the fluorescence in situ hybridization test and/or urinary cytokine expression may constitute a useful approach to predicting intravesical therapy response. Further research into genetic sequencing using large cohorts with follow-up validation is essential to identify novel predictors of response.